NOS2 and neoplasm: The two classical pathways by which MDSCs inhibit T cell anti-tumor immunity are: First, MDSCs that are activated by Th1 cytokines upregulate the expression of inducible nitric oxide synthase (iNOS), which induces NO production, inhibiting T cell responses.